Table 3

Mean changes in clinical characteristics from baseline to 6 months* (primary effectiveness population)

Change over 6 monthsRituximab (n=405)Alternative TNF inhibitor (n=323)p Value*
DAS28-3–ESR†−1.5 (0.2)−1.1 (0.2)0.007
 Improved by at least 0.6, n (%)280 (69.1)191 (59.1)0.005
 Improved by at least 1.6, n (%)156 (38.5)95 (29.4)0.010
DAS28-3–CRP−1.4 (0.3)−1.3 (0.3)0.538
ESR (mm/h)−13.2 (3.9)−7.0 (4.2)0.009
CRP (mg/L)−29.1 (8.0)−29.9 (8.4)0.876
SJC (28 joints)−3.3 (0.9)−2.8 (1.0)0.417
TJC (28 joints)−5.7 (1.2)−4.5 (1.2)0.113
Physician global assessment of disease (mm)−21.0 (6.1)−14.8 (6.7)0.076
Patient global assessment of disease (mm)−17.0 (5.5)−10.2 (5.8)0.044
Patient VAS pain score (mm)−15.7 (6.5)−10.8 (7.0)0.203
HAQ-DI−0.6 (0.2)−0.5 (0.2)0.337
Duration of morning stiffness (min)−19.0 (25.4)−4.3 (27.4)0.325
  • Values are LS mean (SE).

  • *LS means and p values were based on analysis of covariance (ANCOVA) models with change in outcome as the dependent variable and treatment group as the independent variable, with controls for baseline value on the outcome variable, and unbalanced baseline characteristics. p Values for counts were based on the Pearson's χ2 test.

  • †Sensitivity analysis results using ANCOVA with adjustment for the propensity to receive treatment were rituximab −1.3 (0.1) and TNF inhibitor −1.0 (0.1) (p=0.006).

  • CRP, C-reactive protein; DAS28-3, Disease Activity Score in 28 joints excluding patient's global health component; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; LS, least squares; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor; VAS, visual analogue scale.